-
Mashup Score: 3
Odevixibat could be an efficacious non-surgical intervention to improve pruritus, reduce serum bile acids, and enhance the standard of care in patients with Alagille syndrome. Longer-term safety and efficacy data of odevixibat in this population are awaited from the ongoing, open-label ASSERT-EXT study.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 44Review article: Recent advances in ascites and acute kidney injury management in cirrhosis - 22 day(s) ago
Alimentary Pharmacology & Therapeutics is a global pharmacology journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems
Source: onlinelibrary.wiley.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 7
Click on the title to browse this issue
Source: onlinelibrary.wiley.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
be baseline clinical and physiological characteristics in HPS and their relationships, temporal changes in physiological parameters before and after transplant, and predictors of changes in oxygenation. Approach and Results: This was a retrospective cohort study in the Canadian HPS Program (n = 132). Rates of change after diagnosis were: −3.7 (−6.4, −0.96) mm Hg/year for partial pressure of arterial oxygen (PaO2); −26 (−96, 44) m/year for 6-minute walk distance, and 3.3% (−6.6, −0.011) predicted/year for diffusion capacity. Noninvasive shunt of ≥ 20% predicted a slower PaO2 decline by 0.88 (0.36, 1.4) mm Hg/month. We identified 2 PaO2 deterioration classes—“very severe disease, slow decliners” (PaO2 45.0 mm Hg; −1.0 mm Hg/year); and “moderate disease, steady decliners” (PaO2 65.5 mm Hg; −2.5 mm Hg/year). PaO2 increased by 6.5 (5.3, 7.7) mm Hg/month in the first year after transplant. The median time to normalization was 149 (116, 184) days. Posttransplant improvement in PaO2 was 2.5 (0
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5Mechanisms of drug resistance in HCC : Hepatology - 3 month(s) ago
rgeting cell growth and angiogenesis, was approved for advanced unresectable HCC in 2007. Since then, other multikinase inhibitors have been approved. Lenvatinib was found to be noninferior to sorafenib as a first-line agent. Regorafenib, cabozantinib, and ramucirumab were shown to prolong survival as second-line agents. Advances in immunotherapy for HCC have also added hope for patients, but their efficacy remains limited. A large proportion of patients with advanced HCC gain no long-term benefit from systemic therapy due to primary and acquired drug resistance, which, combined with its rising incidence, keeps HCC a highly fatal disease. This review summarizes mechanisms of primary and acquired resistance to therapy and includes methods for bypassing resistance. It addresses recent advancements in immunotherapy, provides new perspectives on the linkage between drug resistance and molecular etiology of HCC, and evaluates the role of the microbiome in drug resistance. It also discusses
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5Mechanisms of drug resistance in HCC : Hepatology - 3 month(s) ago
rgeting cell growth and angiogenesis, was approved for advanced unresectable HCC in 2007. Since then, other multikinase inhibitors have been approved. Lenvatinib was found to be noninferior to sorafenib as a first-line agent. Regorafenib, cabozantinib, and ramucirumab were shown to prolong survival as second-line agents. Advances in immunotherapy for HCC have also added hope for patients, but their efficacy remains limited. A large proportion of patients with advanced HCC gain no long-term benefit from systemic therapy due to primary and acquired drug resistance, which, combined with its rising incidence, keeps HCC a highly fatal disease. This review summarizes mechanisms of primary and acquired resistance to therapy and includes methods for bypassing resistance. It addresses recent advancements in immunotherapy, provides new perspectives on the linkage between drug resistance and molecular etiology of HCC, and evaluates the role of the microbiome in drug resistance. It also discusses
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Heterogeneity, crosstalk, and targeting of... : Hepatology - 3 month(s) ago
al heterogeneity. Besides the tumor cell component, CCA is also characterized by a complex and dynamic tumor microenvironment where tumor cells and stromal cells crosstalk in an intricate network of interactions. Cancer-associated fibroblasts, one of the most abundant cell types in the tumor stroma of CCA, are actively involved in cholangiocarcinogenesis by participating in multiple aspects of the disease including extracellular matrix remodeling, immunomodulation, neo-angiogenesis, and metastasis. Despite their overall tumor-promoting role, recent evidence indicates the presence of transcriptional and functional heterogeneous CAF subtypes with tumor-promoting and tumor-restricting properties. To elucidate the complexity and potentials of cancer-associated fibroblasts as therapeutic targets in CCA, this review will discuss the origin of cancer-associated fibroblasts, their heterogeneity, crosstalk, and role during tumorigenesis, providing an overall picture of the present and future pe
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 10Role of sex in liver tumor occurrence and clinical... : Hepatology - 3 month(s) ago
rently depending on the sex. These observations support the concept that the liver is a sexually dimorphic organ in which estrogen and androgen receptors are present, which results in disparities between men and women in liver gene expression patterns, immune responses, and the progression of liver damage, including the propensity to develop liver malignancies. Sex hormones play protective or deleterious roles depending on the patient’s sex, the severity of the underlying disease, and the nature of precipitating factors. Moreover, obesity, alcohol consumption, and active smoking, as well as social determinants of liver diseases leading to sex-related inequalities, may interact strongly with hormone-related mechanisms of liver damage. Drug-induced liver injury, viral hepatitis, and metabolic liver diseases are influenced by the status of sex hormones. Available data on the roles of sex hormones and gender differences in liver tumor occurrence and clinical outcomes are conflicting. Here,
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 10Role of sex in liver tumor occurrence and clinical... : Hepatology - 3 month(s) ago
rently depending on the sex. These observations support the concept that the liver is a sexually dimorphic organ in which estrogen and androgen receptors are present, which results in disparities between men and women in liver gene expression patterns, immune responses, and the progression of liver damage, including the propensity to develop liver malignancies. Sex hormones play protective or deleterious roles depending on the patient’s sex, the severity of the underlying disease, and the nature of precipitating factors. Moreover, obesity, alcohol consumption, and active smoking, as well as social determinants of liver diseases leading to sex-related inequalities, may interact strongly with hormone-related mechanisms of liver damage. Drug-induced liver injury, viral hepatitis, and metabolic liver diseases are influenced by the status of sex hormones. Available data on the roles of sex hormones and gender differences in liver tumor occurrence and clinical outcomes are conflicting. Here,
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 43A multidisciplinary approach to the diagnosis and... : Hepatology - 3 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, GastroenterologyTweet
New research - Ovchinsky et al - Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial https://t.co/K3uZXFLI4d #LiverTwitter https://t.co/QvvXO52jBI